Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More?

Yu, Ming‐Lung

doi:10.1007/s10620-010-1452-6

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model also describes factors which motivated change and seeking HCV treatment inside prison. Prisoners experienced many factors similar to those which influence treatment uptake of those living with HCV infection in the community [13], [15], [17], [23], [31]–[33]. Incarceration, however, provides different circumstances of how these factors are experienced which need to be better understood if the number of prisoners receiving treatment is to be increased.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

Yap

Carruthers

Thompson³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundHepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world's population infected, and more than 350,000 dying annually from HCV-related conditions including liver failure and liver cancer. Prisons potentially offer a relatively stable environment in which to commence treatment as they usually provide good access to health care providers, and are organised around routine and structure. Uptake of treatment of HCV, however, remains low in the community and in prisons. In this study, we explored factors affecting treatment uptake inside prisons and hypothesised that prisoners have unique issues influencing HCV treatment uptake as a consequence of their incarceration which are not experienced in other populations.Method and FindingsWe undertook a qualitative study exploring prisoners' accounts of why they refused, deferred, delayed or discontinued HCV treatment in prison. Between 2010 and 2013, 116 Australian inmates were interviewed from prisons in New South Wales, Queensland, and Western Australia. Prisoners experienced many factors similar to those which influence treatment uptake of those living with HCV infection in the community. Incarceration, however, provides different circumstances of how these factors are experienced which need to be better understood if the number of prisoners receiving treatment is to be increased. We developed a descriptive model of patient readiness and motivators for HCV treatment inside prisons and discussed how we can improve treatment uptake among prisoners.ConclusionThis study identified a broad and unique range of challenges to treatment of HCV in prison. Some of these are likely to be diminished by improving treatment options and improved models of health care delivery. Other barriers relate to inmate understanding of their illness and stigmatisation by other inmates and custodial staff and generally appear less amenable to change although there is potential for peer-based education to address lack of knowledge and stigma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Treatment could be deferred or delayed if the patient exhibited contraindications such as: decompensated liver disease, medical comorbidities which required medical attention (e.g. cardiovascular disease, diabetes, epilepsy, uncontrolled depression), non-adherence to medical visits, or active drug use [13]–[18].…”

Section: Introductionmentioning

confidence: 99%

A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

Yap

Carruthers

Thompson³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

Protease Inhibitors for Hepatitis C: Economic Implications

2013

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection, a blood-borne virus, is the leading cause of chronic liver disease and liver transplantation worldwide. Chronic HCV infection is usually asymptomatic in the early stages of the disease, making an estimation of the total population affected difficult to elicit. The gold standard treatment option to date has been a combination of pegylated interferon and ribavirin. Recent developments have led to the introduction of two protease inhibitors for use in chronic HCV-boceprevir and telaprevir. Phase III studies have shown both agents have the potential to significantly increase the probability of attaining a sustained virologic response (the primary outcome of interest in chronic HCV) in genotype 1 infections. However, the added cost of these agents also presents the need for decision makers to determine their place on drug formularies. The protease inhibitors are to be administered as triple therapy with the existing gold standard. However, significant variation exists as to the proposed duration of triple therapy, use of lead-in pegylated interferon and ribavirin and subsequent pegylated interferon therapy after finishing the course of triple therapy. Treatment algorithms also exist for the use of stopping rules in the case of early non-responders.The aim of this review is to highlight the current understanding of the economic impact protease inhibitors may have on health care systems and considerations required in the treatment of HCV. Economic and health-related quality of life issues are addressed from multiple viewpoints. The major aspects of the economic evaluations, to date, that included triple therapy as an alternative in the treatment of chronic HCV are brought to light. Future economic evaluations in alternative settings would be useful. The review also emphasizes the challenges for future research. This includes the potential for new therapies to no longer require inclusion of pegylated interferon and/or ribavirin, as well as the use of protease inhibitors in non-genotype 1 patients or those with significant co-morbidities such as HIV/AIDS.

show abstract

Family Psychoeducation for Hepatitis C Patients and Their Families: Recommendation for Clinicians

Simpson

Sims

North³

et al. 2016

Social Work with Groups

View full text Add to dashboard Cite

Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More?

Cited by 4 publications

References 31 publications

A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

Protease Inhibitors for Hepatitis C: Economic Implications

Family Psychoeducation for Hepatitis C Patients and Their Families: Recommendation for Clinicians

Contact Info

Product

Resources

About